4/4/2013

AstraZeneca's MedImmune unit agreed to purchase AlphaCore Pharma, a privately held U.S. biotechnology firm, for an undisclosed amount. The acquisition gives AstraZeneca access to AlphaCore's ACP-501, a cholesterol-lowering drug candidate intended to reduce the risk of heart attack and stroke. The deal is expected to strengthen AstraZeneca's early-stage cardiovascular-drug pipeline.

Related Summaries